

**Table 5. Glaucoma Medications at Baseline in the Ahmed Baerveldt Comparison study**

	Overall Group (n =276 )	AGV Group (n =143 )	BGI Group (n =133 )	P-value <sup>a</sup>
Prostaglandin analogue n (%)	224 (81%)	118 (83%)	106 (80%)	0.64
Beta blocker n (%)	231 (84%)	116(81%)	115 (87%)	0.26
Topical carbonic anhydrase Inhibitor, n (%)	198 (72%)	102 (71%)	96 (73%)	0.89
Alpha <sub>2</sub> agonist, n (%)	195 (71%)	103 (72%)	92 (69%)	0.79
Oral carbonic anhydrase inhibitor, n (%)	80 (29%)	35 (25%)	45 (34%)	0.11
Miotic, n (%)	15 (5%)	7 (5%)	8 (6%)	0.79
Non-selective adrenergic agonist (eg. epinephrine) n (%)	2 (1%)	0 (0%)	2 (2%)	0.23
None, n (%)	4 (1%)	4 (3%)	0 (0%)	0.12

<sup>a</sup>Fisher Exact test

AGV = Ahmed Glaucoma Valve; BGI = Baerveldt Glaucoma Implant